During a live event, Andrew H. Lipsky, MD, and participants discussed balancing efficacy, safety, and patient preferences ...

SELLAS Life Sciences (NASDAQ:SLS) traded higher in the premarket on Tuesday after the New York-based biotech said that a Phase 2 trial that tested its antitumor agent SLS009 (tambiciclib) as part of a ...

AbbVie partners with IGI Therapeutics for ISB 2001, a potential cancer and autoimmune therapy. Read more here.

At a lymphoma conference, experts sparred about treatment options, while an outside expert highlighted the value of each approach.

Data suggest that “venetoclax usage should be avoided in the general relapsed or refractory multiple myeloma population,” the researchers wrote.

Time-limited (or fixed-duration) therapy offers a treatment-free interval, potentially leading to improved quality of life and reduced long-term toxicities. However, it may be less effective for ...

AbbVie remains strong long-term performer, offering a solid dividend yield and robust revenue growth despite share price dips ...

AbbVie announced it will acquire Capstan Therapeutics in a deal worth up to $2.1 billion. TransDigm bought Simmonds, a proximity sensor maker, for $765 million. Shionogi and BioVersys agreed to a deal ...

As part of the deal, AbbVie will acquire Capstan's targeted LNP platform technology and its lead candidate for B cell-mediated autoimmune diseases.

AbbVie will pay up to $2.1 billion in cash at closing to acquire Capstan, subject to certain customary adjustments.